Monitoring of Myeloid Malignancies in the Era of Next Generation Sequencing

Date: Tuesday, Jan 29, 2019

Description: Dr Racke discusses incorporation of new molecular markers into the diagnostic algorithms for myeloid neoplasms, illustrates the principle of molecular monitoring in prognostic and therapeutic assessment of myeloid neoplasms, and explains the benefits and pitfalls in the use of next-generation sequencing (NGS) for the workup of low-grade MDS. At the conclusion of this program, participants will be able to: • Discuss incorporation of new molecular markers into the diagnostic algorithms for myeloid neoplasms • Illustrate the principle of molecular monitoring in prognostic and therapeutic assessment of myeloid neoplasms • Understand the benefits and pitfalls in the use of next-generation sequencing (NGS) for the workup of low-grade MDS ASCLS P.A.C.E.® credits are available to laboratory professionals through July 15, 2019.

Author:
Racke, Frederick K., MD, PhD.
Medical Director, Hematology/Oncology and Coagulation,
Nichols Institute
Quest Diagnostics
San Juan Capistrano, CA